Amneal Pharmaceuticals, Inc.

  • Market Cap: Small Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US03168L1052
USD
12.87
0.05 (0.39%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

52 Week

Valuation
Technical
Day's Volume

CASH

813.48 k

Shareholding (Mar 2025)

FII

4.31%

Held by 107 FIIs

DII

76.39%

Held by 32 DIIs

Promoter

4.53%

What does Amneal Pharmaceuticals, Inc. do?

22-Jun-2025

Amneal Pharmaceuticals, Inc. is a small-cap company in the Pharmaceuticals & Biotechnology industry. It currently has no dividend yield, and its financial metrics indicate significant negative values for debt equity and return on equity.

Overview: <BR>Amneal Pharmaceuticals, Inc. operates in the Pharmaceuticals & Biotechnology industry and is categorized as a small-cap company.<BR><BR>Financial Snapshot: <BR>Market cap: Small Cap<BR><BR>Key Metrics: <BR>Industry: Pharmaceuticals & Biotechnology <BR>Dividend Yield: 0.00% <BR>Debt Equity: -999,999.00 <BR>Return on Equity: -999,999.00% <BR>Price to Book: 0.00 <BR><BR>Contact Details: <BR>Details: No Company Details Available <BR>Registrar Address: Not available.

Read More

Is Amneal Pharmaceuticals, Inc. overvalued or undervalued?

20-Sep-2025

As of March 1, 2024, Amneal Pharmaceuticals, Inc. is considered a risky investment due to its high P/E ratio of 51.39, overvaluation compared to industry peers, and recent stock volatility despite a year-to-date return of 23.86%.

As of 1 March 2024, the valuation grade for Amneal Pharmaceuticals, Inc. has moved from attractive to risky, indicating a shift in perception regarding its investment potential. The company appears to be overvalued, particularly given its high P/E ratio of 51.39 compared to the industry average, which suggests that investors are paying a premium for its earnings. Additionally, the EV to EBITDA ratio stands at 8.71, further supporting the notion of overvaluation.<BR><BR>In comparison to peers, Amneal's valuation metrics are concerning; for instance, its P/E ratio is significantly higher than industry norms, which could deter potential investors. The company’s stock has shown a YTD return of 23.86%, outperforming the S&P 500's 12.22%, but its one-week return of -2.78% contrasts sharply with the S&P 500's positive performance, highlighting recent volatility. Overall, the combination of high valuation ratios and recent performance trends suggests that Amneal Pharmaceuticals may not be a favorable investment at this time.

Read More

Is Amneal Pharmaceuticals, Inc. technically bullish or bearish?

07-Oct-2025

As of October 3, 2025, Amneal Pharmaceuticals shows a bullish technical trend supported by positive MACD and Bollinger Bands, despite some short-term weakness indicated by the weekly RSI, and has significantly outperformed the S&P 500 over three years.

As of 3 October 2025, the technical trend for Amneal Pharmaceuticals, Inc. has changed from mildly bullish to bullish. The weekly and monthly MACD indicators are both bullish, supporting the positive trend. Bollinger Bands also indicate a bullish stance on both weekly and monthly time frames. However, the weekly RSI is bearish, suggesting some short-term weakness, while the monthly RSI shows no signal. The daily moving averages are bullish, reinforcing the overall positive outlook. Dow Theory indicates a mildly bullish trend on the monthly chart, with no trend on the weekly. Additionally, the KST is bullish weekly but mildly bearish monthly, and the OBV shows a mildly bullish stance monthly.<BR><BR>In terms of performance, Amneal has outperformed the S&P 500 across all multi-period returns, notably with a 375.23% return over three years compared to the S&P 500's 82.57%. Overall, the current technical stance is bullish, with strength indicated by multiple bullish signals, despite some mixed indicators in the short term.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
1

Risky - No result in last 6 months

  • The stock is trading risky as compared to its average historical valuations
  • Over the past year, while the stock has generated a return of 64.83%, its profits have fallen by 0%
stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 3,056 Million (Small Cap)

stock-summary
P/E

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-21.41

stock-summary
Return on Equity

-999,999.00%

stock-summary
Price to Book

-27.26

Revenue and Profits:
Net Sales:
725 Million
(Quarterly Results - Jun 2025)
Net Profit:
36 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
30.79%
0%
30.79%
6 Months
62.6%
0%
62.6%
1 Year
65.21%
0%
65.21%
2 Years
123.44%
0%
123.44%
3 Years
485.0%
0%
485.0%
4 Years
153.85%
0%
153.85%
5 Years
190.52%
0%
190.52%

Amneal Pharmaceuticals, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
10.41%
EBIT Growth (5y)
30.81%
EBIT to Interest (avg)
0
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
0
Sales to Capital Employed (avg)
0
Tax Ratio
Tax Ratio is Negative%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
53.67%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
Industry P/E
Price to Book Value
EV to EBIT
EV to EBITDA
EV to Capital Employed
EV to Sales
PEG Ratio
NA
Dividend Yield
ROCE (Latest)
ROE (Latest)
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bullish
Bullish
RSI
No Signal
Bearish
Bollinger Bands
Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Bullish
Mildly Bearish
Dow Theory
Mildly Bullish
Mildly Bullish
OBV
No Trend
Bullish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Mar 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 61 Schemes (14.75%)

Foreign Institutions

Held by 107 Foreign Institutions (4.31%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 3.23% vs 17.16% in Jun 2024",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 111.90% vs -43.43% in Jun 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Jun'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "724.50",
          "val2": "701.80",
          "chgp": "3.23%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "174.10",
          "val2": "153.00",
          "chgp": "13.79%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "65.10",
          "val2": "65.70",
          "chgp": "-0.91%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "-2.70",
          "val2": "-2.00",
          "chgp": "-35.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "35.60",
          "val2": "16.80",
          "chgp": "111.90%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "157.40%",
          "val2": "138.80%",
          "chgp": "1.86%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 16.73% vs 8.20% in Dec 2023",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is -51.75% vs 80.89% in Dec 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "2,794.00",
          "val2": "2,393.60",
          "chgp": "16.73%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "589.50",
          "val2": "492.40",
          "chgp": "19.72%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "258.60",
          "val2": "210.60",
          "chgp": "22.79%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "-104.00",
          "val2": "-100.60",
          "chgp": "-3.38%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-73.90",
          "val2": "-48.70",
          "chgp": "-51.75%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "126.40%",
          "val2": "109.90%",
          "chgp": "1.65%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - YoYstock-summary
Jun'25
Jun'24
Change(%)
Net Sales
724.50
701.80
3.23%
Operating Profit (PBDIT) excl Other Income
174.10
153.00
13.79%
Interest
65.10
65.70
-0.91%
Exceptional Items
-2.70
-2.00
-35.00%
Consolidate Net Profit
35.60
16.80
111.90%
Operating Profit Margin (Excl OI)
157.40%
138.80%
1.86%
USD in Million.
Direction Arrows
Net Sales

YoY Growth in quarter ended Jun 2025 is 3.23% vs 17.16% in Jun 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in quarter ended Jun 2025 is 111.90% vs -43.43% in Jun 2024

Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
2,794.00
2,393.60
16.73%
Operating Profit (PBDIT) excl Other Income
589.50
492.40
19.72%
Interest
258.60
210.60
22.79%
Exceptional Items
-104.00
-100.60
-3.38%
Consolidate Net Profit
-73.90
-48.70
-51.75%
Operating Profit Margin (Excl OI)
126.40%
109.90%
1.65%
USD in Million.
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2024 is 16.73% vs 8.20% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is -51.75% vs 80.89% in Dec 2023

stock-summaryCompany CV
About Amneal Pharmaceuticals, Inc. stock-summary
stock-summary
Amneal Pharmaceuticals, Inc.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates stock-summary
Icon
No Company Details Available